Cardiff Oncology Email Format

Biotechnology ResearchCalifornia, United States51-200 Employees

Cardiff Oncology is a clinical-stage biotechnology company in the biotechnology research industry, headquartered in San Diego, California. The company focuses on developing oncology therapies by inhibiting PLK1, with its lead asset onvansertib, a PLK1 inhibitor. Onvansertib is being evaluated in combination with standard-of-care therapies in clinical programs for KRAS/NRAS-mutated metastatic colorectal cancer and metastatic pancreatic ductal adenocarcinoma, with investigator-initiated trials in triple negative breast cancer and small cell lung cancer. The programs aim to target tumor vulnerabilities to overcome resistance and to improve outcomes relative to standard-of-care. The company employs between 51 and 200 people and, in April 2026, appointed Mani Mohindru as President and Chief Executive Officer.

Get verified Cardiff Oncology emails free

Company overview Employee directory